Filtros de búsqueda

Lista de obras de

A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.

artículo científico publicado en 2017

A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

scientific article published on 18 February 2020

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

artículo científico publicado en 2006

A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma

scientific article published on 20 February 2013

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

artículo científico publicado en 2010

A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.

artículo científico publicado en 2007

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

artículo científico publicado en 2012

A single-dose conformal delivery of radiotherapy following osteoplasty : a novel approach to treatment of osteolytic metastasis in the setting of multiple myeloma

artículo científico publicado en 2011

Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma

artículo científico publicado en 2005

Advances in immunotherapy in multiple myeloma

artículo científico publicado en 2017

Aspirin as thromboprophylaxis in myeloma

artículo científico publicado en 2008

Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma

artículo científico publicado en 2008

BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia

artículo científico publicado en 2002

Best practices in the management of newly diagnosed multiple myeloma patients who will not undergo transplant.

artículo científico publicado en 2010

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

artículo científico publicado en 2007

BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma

artículo científico publicado en 2013

Bortezomib-induced thrombotic thrombocytopaenic purpura

artículo científico publicado en 2012

CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells.

artículo científico publicado en 2009

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.

artículo científico publicado en 2017

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

artículo científico publicado en 2017

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

scientific article published on 28 February 2019

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

artículo científico publicado en 2016

Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR

scholarly article by Athanasios Dimopoulos et al published 10 January 2019 in Blood

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

article

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

artículo científico publicado en 2017

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups

artículo científico publicado en 2019

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study

artículo científico publicado en 2017

Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients

artículo científico publicado en 2017

Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.

artículo científico publicado en 2010

Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma

scientific article published on 11 January 2019

Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.

artículo científico publicado en 2016

Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma

artículo científico publicado en 2010

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay

artículo científico publicado en 2016

Clinical characteristics of patients with relapsed multiple myeloma

artículo científico publicado en 2015

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

artículo científico publicado en 2005

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens

artículo científico publicado en 2015

Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia

artículo científico publicado en 2010

Conflicts of interest, authorship, and disclosures in industry-related scientific publications

artículo científico publicado en 2010

Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myeloma

artículo científico publicado en 2016

Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

scientific article published on 19 April 2020

Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11

artículo científico publicado en 2008

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

artículo científico publicado en 2009

FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma

artículo científico publicado en 2008

Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells

artículo científico publicado en 2005

Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma

artículo científico publicado en 2020

Gallium nitrate in multiple myeloma: prolonged survival in a cohort of patients with advanced-stage disease

artículo científico publicado en 2003

Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma.

artículo científico publicado en 2018

Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices

artículo científico publicado en 2017

Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

artículo científico publicado en 2016

Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients

scientific article published on 13 August 2019

High-Cutoff Hemodialysis in Myeloma Cast Nephropathy

artículo científico publicado en 2017

High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma

artículo científico publicado en 2019

How lenalidomide is changing the treatment of patients with multiple myeloma

artículo científico

IMWG consensus on maintenance therapy in multiple myeloma

artículo científico publicado en 2012

Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies

artículo científico publicado en 2017

IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease

artículo científico publicado en 2013

IgM myeloma: A multicenter retrospective study of 134 patients

artículo científico publicado en 2017

Immunomodulatory agents changing the landscape of multiple myeloma treatment

artículo científico publicado en 2013

Impact of early response to sequential high-dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features

artículo científico publicado en 2002

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

artículo científico publicado en 2013

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

artículo científico publicado en 2011

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

artículo científico publicado en 2014

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

artículo científico publicado en 2019

Kyphoplasty enhances function and structural alignment in multiple myeloma.

artículo científico publicado en 2004

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

artículo científico publicado en 2009

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

artículo científico publicado en 2007

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy

artículo científico publicado en 2007

Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma

artículo científico publicado en 2008

MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin

artículo científico publicado en 2011

Milatuzumab: a promising new agent for the treatment of lymphoid malignancies

artículo científico publicado en 2009

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

artículo científico publicado en 2009

Monoclonal gammopathy of undetermined significance: a consensus statement

artículo científico publicado en 2010

Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma

artículo científico publicado en 2005

Necrotizing soft tissue infection in two patients with multiple myeloma

artículo científico

Novel agents in myeloma: an exciting saga

artículo científico publicado en 2009

Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma

artículo científico publicado en 2008

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

artículo científico publicado en 2020

Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

scientific article published on 29 May 2019

Outcome of deferred initial therapy in mantle-cell lymphoma

artículo científico publicado en 2009

Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization

artículo científico publicado en 2013

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

artículo científico publicado en 2014

Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.

artículo científico publicado en 2018

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

artículo científico publicado en 2015

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

artículo científico publicado en 2013

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

artículo científico publicado en 2010

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

scholarly article by A Keith Stewart et al published 4 February 2019 in Blood Cancer Journal

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

artículo científico publicado en 2009

Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma

artículo científico publicado en 2013

Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma

scientific article published on 25 February 2019

Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma.

artículo científico publicado en 2009

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

artículo científico publicado en 2013

Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma

artículo científico publicado en 2016

Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma

artículo científico

Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy

artículo científico publicado en 2008

Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.

artículo científico publicado en 2012

Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma

artículo científico publicado en 2007

Pulmonary hypertension complicating multiple myeloma

artículo científico publicado en 2015

Re: When you look matters: the effect of assessment schedule on progression-free survival

artículo científico publicado en 2008

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

artículo científico publicado en 2010

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

artículo científico publicado en 2014

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

artículo científico publicado en 2005

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

scientific article published on 27 September 2012

Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma

artículo científico publicado en 2015

Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma

artículo científico publicado en 2008

Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma

artículo científico publicado en 2006

Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone

artículo científico publicado en 2009

Sustained disease control in transplant-ineligible patients: the role of continuous therapy

scientific article published on 01 November 2012

Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma

artículo científico

The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation

artículo científico publicado en 2005

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

artículo científico publicado en 2008

Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone

artículo científico publicado en 2003

Treatment of multiple myeloma with carfilzomib in patients with renal injury.

artículo científico publicado en 2013

Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment

artículo científico

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma

artículo científico publicado en 2008

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda